Therapeutic Glaucoma

>

Latest News

Nicox, Glaukos sign exclusive NCX 1728 research and global licensing option agreement
Nicox, Glaukos sign exclusive NCX 1728 research and global licensing option agreement

September 23rd 2024

The option gives Glaukos exclusive global license agreements on pre-agreed terms, including upfront and milestone payments plus royalties.

ViaLase receives CE mark for first femtosecond laser for treatment of glaucoma
ViaLase receives CE mark for first femtosecond laser for treatment of glaucoma

July 30th 2024

Stuart Therapeutics announces licensing deal with Glaukos
Stuart Therapeutics announces licensing deal with Glaukos

October 19th 2023

Skye Bioscience and NextPharma complete production and filling of SBI-100 in preparation for upcoming phase 2a clinical trial
Skye Bioscience and NextPharma complete production and filling of SBI-100 in preparation for upcoming phase 2a clinical trial

July 8th 2023

VVN539 meets primary study endpoints in US phase IIa clinical study
VVN539 meets primary study endpoints in US phase IIa clinical study

June 5th 2023

Video Interviews
Podcasts

More News

© 2024 MJH Life Sciences

All rights reserved.